Catalyst Pharmaceuticals, Inc. (CPRX)
Company Info
| ISIN | US14888U1016 |
|---|---|
| CUSIP | 14888U101 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $2.07B |
|---|---|
| EPS (TTM) | $0.56 |
| PE Ratio | 31.27 |
| Total Revenue (TTM) | $311.77M |
| Gross Profit (TTM) | $260.21M |
| EBITDA (TTM) | $58.77M |
| Year Range | $11.55 - $17.99 |
| Target Price | $27.29 |
| Short % | 5.63% |
| Short Ratio | 4.01 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: CPRX vs. CL, CPRX vs. XPEL, CPRX vs. TPL, CPRX vs. BMRN, CPRX vs. MOH, CPRX vs. AADI, CPRX vs. ENSG, CPRX vs. SPY, CPRX vs. FLGT, CPRX vs. QQQ
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Catalyst Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Catalyst Pharmaceuticals, Inc. had a return of 3.33% year-to-date (YTD) and 30.50% in the last 12 months. Over the past 10 years, Catalyst Pharmaceuticals, Inc. had an annualized return of 22.25%, outperforming the S&P 500 benchmark which had an annualized return of 10.58%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 3.33% | 13.20% |
| 1 month | 14.65% | -1.28% |
| 6 months | 19.55% | 10.32% |
| 1 year | 30.50% | 18.23% |
| 5 years (annualized) | 28.88% | 12.31% |
| 10 years (annualized) | 22.25% | 10.58% |
Monthly Returns
The table below presents the monthly returns of CPRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -14.34% | 11.32% | -0.56% | -5.58% | 7.44% | -4.21% | 3.33% | ||||||
| 2023 | -16.72% | -1.48% | 8.65% | -3.98% | -27.45% | 16.36% | 2.90% | 1.52% | -16.74% | 6.16% | 16.28% | 16.49% | -9.62% |
| 2022 | -14.92% | 35.42% | 6.28% | -8.08% | -5.51% | -2.64% | 46.08% | 32.23% | -5.24% | 8.11% | 20.91% | 10.91% | 174.74% |
| 2021 | 8.98% | 6.87% | 18.51% | -0.65% | 20.74% | 3.98% | 1.57% | -5.65% | -3.81% | 11.32% | 18.64% | -3.29% | 102.69% |
| 2020 | 9.60% | 2.43% | -8.55% | 23.12% | -9.07% | 7.19% | -6.93% | -23.72% | -9.45% | -0.00% | 23.23% | -8.74% | -10.93% |
| 2019 | 31.25% | 15.48% | 75.26% | 12.55% | -39.02% | 9.71% | 29.95% | 23.45% | -13.80% | -10.92% | -1.90% | -19.18% | 95.31% |
| 2018 | -13.30% | -5.90% | -25.08% | 17.15% | 37.14% | -18.75% | -7.37% | 16.61% | 12.17% | -21.16% | -14.93% | -24.26% | -50.90% |
| 2017 | 6.67% | 0.89% | 72.57% | -5.64% | 15.22% | 30.19% | 6.52% | -6.46% | -8.36% | 13.49% | 50.35% | -9.07% | 272.38% |
| 2016 | -24.08% | -43.55% | 11.43% | -41.88% | -9.56% | 15.45% | 1.41% | 40.28% | 7.92% | -3.67% | 3.81% | -3.67% | -57.14% |
| 2015 | 22.90% | 3.01% | 15.16% | -27.02% | 25.00% | 4.56% | 19.61% | -26.52% | -17.36% | 5.33% | -14.08% | -9.76% | -17.51% |
| 2014 | 0.00% | 14.87% | 0.89% | -7.96% | 5.77% | 15.00% | -10.28% | 40.97% | 3.75% | -10.54% | -10.77% | 12.08% | 52.31% |
| 2013 | 19.54% | -11.92% | 7.03% | 54.02% | 17.88% | 0.67% | 45.09% | 49.23% | 57.22% | -46.89% | 6.17% | 13.37% | 348.28% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CPRX is 70, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Catalyst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Catalyst Pharmaceuticals, Inc. was 94.25%, occurring on Nov 12, 2012. Recovery took 1717 trading sessions.
The current Catalyst Pharmaceuticals, Inc. drawdown is 17.48%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.25% | Feb 2, 2007 | 1429 | Nov 12, 2012 | 1717 | Sep 10, 2019 | 3146 |
| -64.87% | Sep 12, 2019 | 128 | Mar 16, 2020 | 424 | Nov 17, 2021 | 552 |
| -45.37% | Jan 17, 2023 | 92 | May 26, 2023 | — | — | — |
| -38.21% | Nov 10, 2006 | 49 | Jan 24, 2007 | 5 | Jan 31, 2007 | 54 |
| -28.72% | Nov 18, 2021 | 48 | Jan 27, 2022 | 11 | Feb 11, 2022 | 59 |
Volatility
Volatility Chart
The current Catalyst Pharmaceuticals, Inc. volatility is 8.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Catalyst Pharmaceuticals, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |